Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Mark Samaan, Corey A. Siegel et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortKelvin T. Thia, Edward V. Loftus|Gastroenterology|2010Cited by 781
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states communityKiran Bambha, L. Joseph Melton, W. Ray Kim et al.|Gastroenterology|2003Cited by 452
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysisDavid Kotlyar, Gary R. Lichtenstein, James D. Lewis et al.|Clinical Gastroenterology and Hepatology|2014Cited by 405
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Remo Panaccione et al.|The Lancet|2022Cited by 383